Navigation Links
TessArae Delivers Lower Cost Option to Genetic Testing Market
Date:11/9/2009

POTOMAC FALLS, Va., Nov. 9 /PRNewswire/ -- TessArae® LLC, a global leader in resequencing microarray-based applications, announces the launch of new integrated product solutions for genetic testing of the mutations that underlie human hereditary diseases. The combination of TessArae's expertise in microarray-based resequencing with novel nucleotide sequence basecalling algorithms and analysis software enables screening for all targeted mutations in multiple genes of a syndrome or disorder simultaneously. This dramatically reduces total testing cost and time-to-result without compromising test accuracy and usability for providers of genetic testing services. The first solution, offered by GeneDx (Gaithersburg, MD), is for Noonan Syndrome, a genetic disorder that causes abnormal development of multiple parts of the body. "Implementation of the custom-designed resequencing solution from TessArae, which simultaneously detects all known mutations and screens for missense mutations in eight genes of the RAS/MAPK pathway, allows GeneDx to offer a more comprehensive test than we could previously, yet at significantly lower cost and with much faster turnaround time," states John Compton, Ph.D., Co-President and Scientific Director of GeneDx. "Based on the successful integration of this technology into our laboratory workflow, we plan to offer TessArae-developed resequencing microarray-based testing for Periodic Fever Syndromes in the immediate future." According to Klaus Schafer, M.D., MPH, President and CEO of TessArae, "The human genetic disease testing market represents a new opportunity for us. Our resequencing microarray-based solution is ideally positioned, from both a cost and time-to-result perspective, between conventional and next-gen DNA sequencing technologies, and will generate significant revenue as the genetic testing market grows."

About TessArae: TessArae's TessArray® RPM (Resequencing Pathogen Microarray) technology simultaneously detects and identifies numerous viral, bacterial, and fungal pathogens, from clinical, environmental and product samples, enabling characterization -- to the strain level -- all in a same-day, single-sample, multiple-result test. TessArae's technology is the only multiplexed genotypic technology that provides direct nucleotide sequence information from pathogen-specific genomic signatures. TessArae has several commercially available products for Research Use Only purposes, including the RPM-Flu Kit for detection and definitive identification of respiratory pathogens, the RPM-TEI Kit for tropical and emerging infections, and the RPM-HFV Kit for whole genome resequencing of HFV hemorrhagic fever viruses. TessArae is based in Potomac Falls, Loudoun County, VA just outside Washington, DC. TessArae products are not intended for in vitro diagnostic use or for patient treatment decisions.

SOURCE TessArae, LLC


'/>"/>
SOURCE TessArae, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
2. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study
3. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
4. VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers
5. Vtech(R) Delivers Todays Hottest Trends to Tech-Savvy Kids
6. Hoviones TwinCaps(R) Inhaler Delivers Successfully in Phase III Clinical Trials for Influenza
7. Ethicon Endo-Surgery Launches New Echelon Flex(TM) Endopath(R) Stapler That Delivers Echelon(TM) Compression, Now With Natural Articulation
8. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
9. Siemens Delivers Flash Speed, Lowest Dose to Arnold Palmer Hospital for Children
10. Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75
11. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016  PipelineRx, a leading medication management ... offering demonstrations of its SaaS-based telepharmacy platform, ... Pharmacists 2016 Midyear Clinical Meeting and Exhibition, December ... With nearly 300 hospital clients nationally, the Company ... designed to dramatically improve pharmacy operations, enhance patient ...
(Date:12/2/2016)... -- On Thursday, December 1st 2016, the ... development and innovation in the biopharmaceutical industry at its ... the presence of Sergey Tsyb, Vice Minister of Industry ... , Natalia Sanina, First Vice Chairman of the State ... Roszdravnadzor, National Service of Control in Healthcare, Sergey Muravev, ...
(Date:12/2/2016)... Dec. 2, 2016  Eli Lilly and Company (NYSE: ... for 2017 and provide updated financial guidance for 2016 ... a conference call on that day with the investment ... guidance. The conference call will begin at ... can access a live webcast of the conference call ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... 03, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... New York City, with long-time partners The Paul Foundation, on November 10, 2016. ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... Entrepreneurial Company in the Dallas area” Tuesday evening at the 26th Annual SMU ... presented by SMU's Cox School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by ...
(Date:12/4/2016)... , ... December 04, 2016 , ... Responsible dental care ... must brush properly to achieve optimal results. This important necessity inspired an inventor from ... for a way to ensure that people break or avoid bad techniques of brushing ...
(Date:12/2/2016)... SAN DIEGO, Calif. (PRWEB) , ... December 02, 2016 , ... ... Recognition Event at the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight ... as myeloproliferative neoplasms (MPNs) by going above and beyond the standard of care, demonstrating ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... announces the launch of its 60-day free trial program for all of the ... make the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers ...
Breaking Medicine News(10 mins):